Initial surgical management of advanced epithelial ovarian cancer

Cancer Investigation

Volumn 15, Issue 3, 1997, Pages 270-276

  Benjamin, Ivor ^a   Rubin, Stephen C ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ANALYTIC METHOD; ARTICLE; CANCER STAGING; CAUSE OF DEATH; EPITHELIUM CELL; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MASS SCREENING; OVARY CANCER; PRIORITY JOURNAL; SURGICAL TECHNIQUE;

EID: 0030984972     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909709039726     Document Type: Article

References (35)

1. NIH consensus conference: Ovarian cancer: Screening, treatment, and follow-up. JAMA 273:491-497, 1995.
2. Averette HE, Hoskins W, Nguyen HN, et al: National survey of ovarian carcinoma. I. A patient care evaluation study of the American College of Surgeons. Cancer 71:1629-1638, 1993.
3. Wingo PA, Tong T, Bolden S: Cancer statistics, 1995. Ca Cancer J Clin 45:8-30, 1995.
4. Pettersson F: Annual report on the results of treatment in gynecological cancer. Twenty-first volume. Statements of results obtained in patients treated in 1982 to 1986, inclusive 3 and 5-year survival up to 1990. Int J Gynaecol Obstet 36:1-315, 1991.
5. Nelson BE, Rosenfield AT, Schwartz PE: Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol 11: 166-72, 1993.
6. Morris M, Gershenson DM, Burke TW, Wharton JT, Copeland LJ, Rutledge FN: Splenectomy in gynecologic oncology: indications, complications, and technique. Gynecol Oncol 43:118-122, 1991.
7. Sonnendecker EW, Guidozzi F, Margolius KA: Splenectomy during primary maximal cytoreductive surgery for epithelial ovarian cancer. Gynecol Oncol 35:301-306, 1989.
8. Buchsbaum KJ, Brady MF, Delgado G, et al: Surgical staging of carcinoma of the ovaries. Surg Gynecol Obstet 169:226-232, 1989.
9. Tsuruchi N, Kamura T, Tsukamoto N, et al: Relationship between paraaortic lymph node involvement and intraperitoneal spread in patients with ovarian cancer - A multivariate analysis. Gynecol Oncol 49:51-55, 1993.
10. Burghardt E, Girardi F, Lahfousen M, Tamussino K, Stettner H: Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecol Oncol 40:103-106, 1991.
11. McGowan L, Lesher LP, Norris HJ, Barnett M: Misstaging of ovarian cancer. Obstet Gynecol 65:568-572, 1985.
12. Nguyen HN, Averette HE, Hoskins W, Penalver M, Sevin BU, Steren A: National survey of ovarian carcinoma. Part V. The impact of physician's specialty on patients' survival. Cancer 72:3663-3670, 1993.
13. Young RC, Decker DG, Wharton JT, et al: Staging laparotomy in early ovarian cancer. JAMA 250:3072-3076, 1983.
14. Piver MS, Barlow JJ, Lele SB: Incidence of subclinical metastasis in stage I and II ovarian carcinoma. Obstet Gynecol 52:100-104, 1978.
15. Helewa ME, Krepart GV, Lotocki R: Staging laparotomy in early epithelial ovarian carcinoma. Am J Obstet Gynecol 154:282-286, 1986.
16. Chen SS, Bochner R: Assessment of morbidity and mortality in primary cytoreductive surgery for advanced ovarian carcinoma. Gynecol Oncol 20:190-195, 1985.
17. Griffiths CT, Parker LM, Fuller AJ: Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep 63:235-240, 1979.
18. Hacker NF, Berek JS, Lagasse LD, Nieberg RK, Elashoff RM: Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 61:413-420, 1983.
19. Piver MS, Baker T: The potential for optimal (less than or equal to 2 cm) cytoreductive surgery in advanced ovarian carcinoma at a tertiary medical center: a prospective study. Gynecol Oncol 24:1-8, 1986.
20. Wu PC, Qu JY, Lang JH, Huang RL, Tang MY, Lian LJ: Lymph node metastasis of ovarian cancer: A preliminary survey of 74 cases of lymphadenectomy. Am J Obstet Gynecol 155:1103-1108, 1986.
21. Burghardt E, Lahousen M, Stettner H: The significance of pelvic and para-aortic lymphadenectomy in the operative treatment of ovarian cancer. Baillieres Clin Obstet Gynaecol 3:157-65, 1989.
22. Burghardt E, Pickel H, Lahousen M, Stettner H: Pelvic lymphadenectomy in operative treatment of ovarian cancer. Am J Obstet Gynecol 155:315-319, 1986.
23. Eisenkop SM, Spirtos NM, Montag TW, Nalick RH, Wang HJ: The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol 47:203-209, 1992.
24. Griffiths CT: Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 42:101-104, 1975.
25. Conte PF, Bruzzone M, Chiara S, et al: A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer [published erratum appears in J Clin Oncol 4(8):1284, 1986]. J Clin Oncol 4:965-971, 1986.
26. Delgado G, Oram DH, Petrilli ES: Stage III epithelial ovarian cancer: The role of maximal surgical reduction. Gynecol Oncol 18:293-298, 1984.
27. Neijt J, ten Bokkel Huinink W, van der Burg M, et al: Randomized trial comparing two combination chemotherapy regimens (CHAP-5 vs CP) in advanced ovarian carcinoma. J Clin Oncol 5:1157-1168, 1987.
28. Vogl S, Pagano M, Kaplan B, Greenwald E, Arseneau J, Bennett B: Cisplatin based combination chemotherapy for advanced ovarian cancer. High overall response rate with curative potential only in women with small tumor burdens. Cancer 51:2024-2030, 1983.
29. Young R, Chabner B, Hubbard S, et al: Advanced ovarian adeno-carcinoma: A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med 299:1261-1266, 1978.
30. Pohl R, Dallenback-Hellweg G, Plugge T, Czernobilsky B: Prognostic parameters in patients with advanced ovarian malignant tumors. Eur J Gynaec Oncol 3:160-169, 1984.
31. Omura GA, Bundy BN, Berek JS, Curry S, Delgado G, Mortel R: Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: A Gynecologic Oncology Group Study, J Clin Oncol 7:457-465, 1989.
32. Piver MS, Lele SB, Marchetti DL, Baker TR, Tsukada Y, Emrich LJ: The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma. J Clin Oncol 6:983-989, 1988.
33. Hoskins WJ, Rubin SC: Surgery in the treatment of patients with advanced ovarian cancer. Semin Oncol 18:213-221, 1991.
34. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA: The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: A Gynecologic Oncology Group study. Gynecol Oncol 47:159-166, 1992.
35. Hoskins WJ, McGuire WP, Brady MF, et al: The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 170:974-979; discussion 979-980, 1994.